Prelude Capital Management, LLC Aldeyra Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $13,652 - $25,699	-3,413 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $6,723 - $17,235	3,413 New	3,413 $14,000
Q1 2020 May 15, 2020	SELL	$1.62 - $6.4 $2,980 - $11,776	-1,840 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.73 - $7.98 $1,513 - $2,553	-320 Reduced 14.81%	1,840 $11,000
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $1,146 - $1,591	-260 Reduced 10.74%	2,160 $11,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $960 - $1,440	-160 Reduced 6.2%	2,420 $15,000
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $57 - $78	8 Added 0.31%	2,580 $23,000
Q4 2018 Feb 14, 2019	SELL	$7.26 - $13.29 $10,890 - $19,935	-1,500 Reduced 36.84%	2,572 $21,000
Q3 2018 Nov 14, 2018	SELL	$6.8 - $14.35 $117,932 - $248,872	-17,343 Reduced 80.99%	4,072 $56,000
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $129,853 - $171,519	18,684 Added 684.15%	21,415 $170,000
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $9,025 - $12,264	1,378 Added 101.85%	2,731 $20,000
Q4 2017 Feb 14, 2018	SELL	$5.7 - $7.75 $62 - $85	-11 Reduced 0.81%	1,353 $9,000
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $5,319 - $14,731	1,364	1,364 $10,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.